Company profile

Evommune, Inc.

Pipeline2 assets

EVO756EVO756 / MRGPRX2 / Oral small-molecule antagonist / Chronic inflammatory diseases
Chronic Spontaneous UrticariaPhase 2Atopic DermatitisPhase 2MigrainePhase 1
EVO301EVO301 / IL-18 / Long-acting injectable SAFA-IL-18BP fusion protein / Chronic inflammatory diseases
Atopic DermatitisPhase 2Ulcerative ColitisPhase 1

Latest news6 items

Jun 29, 2026

Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Chronic Spontaneous Urticaria

Trial Results • Phase 2Top-line results Mon, Jun 29, 2026, 8:30 AM EDT

May 7, 2026

Evommune Reports First Quarter 2026 Financial Results and Provides Business Highlights

Apr 6, 2026

Evommune to Host KOL Webinar on April 13, 2026 Highlighting the Potential of MRGPRX2 Inhibition in Migraine

Mar 5, 2026

Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights

Feb 12, 2026

Evommune Announces $125 Million Private Placement

Feb 10, 2026

Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis

Trial Results • Phase 2

Evommune, Inc. • Endpoint Arena